{"denoms":[{"counts":[{"groupId":"BG000","value":"12"}],"units":"Participants"}],"groups":[{"description":"This is an open label study.\n\n* Pembrolizumab 200 mg IV every 3 weeks and lenalidomide 25 mg po daily x 14 days and dexamethasone 40 mg po once weekly for a 21-day cycle x 2 cycles.\n* This is followed by pembrolizumab 200 mg every 3 weeks and lenalidomide 25 mg po daily x 14 days for a 21-day cycle x 2 cycles for a total of 4 cycles.\n\nPembrolizumab: Pembrolizumab 200 mg IV every 3 weeks x 2 cycles. This is followed by followed by pembrolizumab 200 mg IV every 3 weeks for 2 additional cycles.\n\nLenalidomide: Lenalidomide 25 mg po daily x 14 days once weekly for a 21-day cycle x 2 cycles. This is followed by lenalidomide 25 mg po daily x 14 days for a 21-day cycle x 2 cycles for 2 additional cycles.\n\nDexamethasone: Dexamethasone 40 mg po once weekly for a 21-day cycle x 2 cycles only.","id":"BG000","title":"Pembrolizumab + Lenalidomide"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"63.9","upperLimit":"70.2","value":"67.2"}]}],"title":"Age"}],"dispersionType":"FULL_RANGE","paramType":"MEAN","title":"Age, Customized","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"5"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"7"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"10"}]}],"title":"White"},{"categories":[{"measurements":[{"groupId":"BG000","value":"2"}]}],"title":"Non-White"}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race/Ethnicity, Customized","unitOfMeasure":"Participants"}]}